Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review
AbstractTo date, there is no final FDA-approved treatment for COVID-19. There are thousands of studies published on the available treatments for COVID-19 virus in the past year. Therefore, it is crucial to synthesize and summarize the evidence from published studies on the safety and efficacy of exp...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2021-01-01
|
| Series: | Annals of Medicine |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/07853890.2021.1875500 |
| _version_ | 1797385734771965952 |
|---|---|
| author | Ahmed Wadaa-Allah Marwa S. Emhamed Mohammed A. Sadeq Nesrine Ben Hadj Dahman Irfan Ullah Nesrine S. Farrag Ahmed Negida |
| author_facet | Ahmed Wadaa-Allah Marwa S. Emhamed Mohammed A. Sadeq Nesrine Ben Hadj Dahman Irfan Ullah Nesrine S. Farrag Ahmed Negida |
| author_sort | Ahmed Wadaa-Allah |
| collection | DOAJ |
| description | AbstractTo date, there is no final FDA-approved treatment for COVID-19. There are thousands of studies published on the available treatments for COVID-19 virus in the past year. Therefore, it is crucial to synthesize and summarize the evidence from published studies on the safety and efficacy of experimental treatments of COVID-19. We conducted a systematic literature search of MEDLINE, PubMed, Cochrane Library, GHL, OpenGrey, ICTRP, and ClinicalTrials.gov databases through April 2020. We obtained 2699 studies from the initial literature search. Of them, we included 28 eligible studies that met our eligibility criteria. The sample size of the included studies is 2079 individuals. We extracted and pooled the available data and conducted a quality assessment for the eligible studies. From the 28 studies, only 13 studies provide strong evidence. Our results showed that Favipiravir and Hydroxycholoroquine shorten viral clearance and clinical recovery time and promote pneumonia absorption. On the other hand, Lopinavir-ritonavir either alone or combined with arbidol or interferons has no significant difference superior to the standard care. Corticosteroids, Convalescent plasma transfusion, and anticoagulant therapies provide a better prognosis. Remedsivir, Tocilizumab, Immunoglobulin, Mesenchymal stem cell transplantation showed effective treatment results, but further confirmatory studies are needed. In conclusion, Favipiravir and Remedsivir might be promising drugs in the treatment of COVID-19 patients. |
| first_indexed | 2024-03-08T21:58:32Z |
| format | Article |
| id | doaj.art-e37e796a98004191a231472651454ee5 |
| institution | Directory Open Access Journal |
| issn | 0785-3890 1365-2060 |
| language | English |
| last_indexed | 2024-03-08T21:58:32Z |
| publishDate | 2021-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Annals of Medicine |
| spelling | doaj.art-e37e796a98004191a231472651454ee52023-12-19T16:46:27ZengTaylor & Francis GroupAnnals of Medicine0785-38901365-20602021-01-0153131833410.1080/07853890.2021.1875500Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping reviewAhmed Wadaa-Allah0Marwa S. Emhamed1Mohammed A. Sadeq2Nesrine Ben Hadj Dahman3Irfan Ullah4Nesrine S. Farrag5Ahmed Negida6Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, EgyptFaculty of Medicine, Tripoli University, Tripoli, LibyaFaculty of Medicine, Misr University, Cairo, EgyptFaculty of Medicine of Tunis, University of Tunis El Manar, Tunis, TunisiaKabir Medical College, Gandhara University, Peshawar, PakistanCommunity Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, EgyptZagazig University Hospitals, Zagazig University, El-Sharkia, EgyptAbstractTo date, there is no final FDA-approved treatment for COVID-19. There are thousands of studies published on the available treatments for COVID-19 virus in the past year. Therefore, it is crucial to synthesize and summarize the evidence from published studies on the safety and efficacy of experimental treatments of COVID-19. We conducted a systematic literature search of MEDLINE, PubMed, Cochrane Library, GHL, OpenGrey, ICTRP, and ClinicalTrials.gov databases through April 2020. We obtained 2699 studies from the initial literature search. Of them, we included 28 eligible studies that met our eligibility criteria. The sample size of the included studies is 2079 individuals. We extracted and pooled the available data and conducted a quality assessment for the eligible studies. From the 28 studies, only 13 studies provide strong evidence. Our results showed that Favipiravir and Hydroxycholoroquine shorten viral clearance and clinical recovery time and promote pneumonia absorption. On the other hand, Lopinavir-ritonavir either alone or combined with arbidol or interferons has no significant difference superior to the standard care. Corticosteroids, Convalescent plasma transfusion, and anticoagulant therapies provide a better prognosis. Remedsivir, Tocilizumab, Immunoglobulin, Mesenchymal stem cell transplantation showed effective treatment results, but further confirmatory studies are needed. In conclusion, Favipiravir and Remedsivir might be promising drugs in the treatment of COVID-19 patients.https://www.tandfonline.com/doi/10.1080/07853890.2021.1875500CoronavirusdrugstreatmentSARS-COV-2COVID-19 |
| spellingShingle | Ahmed Wadaa-Allah Marwa S. Emhamed Mohammed A. Sadeq Nesrine Ben Hadj Dahman Irfan Ullah Nesrine S. Farrag Ahmed Negida Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review Annals of Medicine Coronavirus drugs treatment SARS-COV-2 COVID-19 |
| title | Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review |
| title_full | Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review |
| title_fullStr | Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review |
| title_full_unstemmed | Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review |
| title_short | Efficacy of the current investigational drugs for the treatment of COVID-19: a scoping review |
| title_sort | efficacy of the current investigational drugs for the treatment of covid 19 a scoping review |
| topic | Coronavirus drugs treatment SARS-COV-2 COVID-19 |
| url | https://www.tandfonline.com/doi/10.1080/07853890.2021.1875500 |
| work_keys_str_mv | AT ahmedwadaaallah efficacyofthecurrentinvestigationaldrugsforthetreatmentofcovid19ascopingreview AT marwasemhamed efficacyofthecurrentinvestigationaldrugsforthetreatmentofcovid19ascopingreview AT mohammedasadeq efficacyofthecurrentinvestigationaldrugsforthetreatmentofcovid19ascopingreview AT nesrinebenhadjdahman efficacyofthecurrentinvestigationaldrugsforthetreatmentofcovid19ascopingreview AT irfanullah efficacyofthecurrentinvestigationaldrugsforthetreatmentofcovid19ascopingreview AT nesrinesfarrag efficacyofthecurrentinvestigationaldrugsforthetreatmentofcovid19ascopingreview AT ahmednegida efficacyofthecurrentinvestigationaldrugsforthetreatmentofcovid19ascopingreview |